


Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 018733-1055	SERIAL NO. 09/924,103
<b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)		APPLICANT David M. GOLDENBERG, et al.	
		FILING DATE 08/08/2001	GROUP ART UNIT <del>1646</del> 1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
							RECEIVED
							FEB 11 2002
							TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
CY	A1	2,279,474	01/31/2000	Canada				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CY	A2	P. Caron et al., "Supersaturating Infusional Humanized Anti-CD33 Monoclonal Antibody HuM195 in Myelogenous Leukemia <sup>1</sup> ," <u>Clinical Cancer Research</u> , Vol. 4, pgs. 1421-1428, June 1998.						
CY	A3	H. Hansen et al., "Characterization of Second-Generation Monoclonal Antibodies Against Carcinoembryonic Antigen," <u>Cancer</u> , Vol. 71, No. 11, pgs. 3478-3485, June 1993.						
CY	A4	J. Kotzerke et al., "Use of Re-188-Labeled Anti NCA-95 Antibodies in Treatment of Leukemia: First Results," <u>Journal of Nuclear Medicine</u> , Vol. 40, No. 5, May 1999, Abstract.						
CY	A5	R. Di Noto et al., "In Vitro Treatment of APL Cells with Arsenic Trioxide (As <sub>2</sub> O <sub>3</sub> ) Results in a Highly Specific Induction of Solitary CD66c Display," <u>Blood</u> , Vol. 90, No. 10, November 1997, Abstract.						

EXAMINER <i>Christopher H X</i>	DATE CONSIDERED 2-12-03
------------------------------------	----------------------------

\* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.